

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

---

In re PLAVIX MARKETING,  
SALES PRACTICE AND PRODUCTS  
LIABILITY LITIGATION (NO. II)

---

MDL DOCKET NO. 2418

Civil Action No. 13-1039 (FLW)(LHG)

**AMENDED ORDER**

UNITED STATES OF AMERICA, *et al.*,  
ex rel. ELISA DICKSON,

Plaintiffs,

v.

BRISTOL-MYERS SQUIBB CO., *et al.*,

Defendants.

---

**THIS MATTER** having been opened to the Court by Lowenstein Sander LLP (Gavin J. Rooney, Esq., appearing), counsel for Defendants Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Sanofi US Services Inc., and Sanofi-Synthelabo, Inc. (“Defendants”), on a motion to dismiss the Fourth Amended Complaint (“4AC”) of Relator Elisa Dickson (“Relator”); it appearing that Relator, through counsel Christopher Cueto, Esq., opposes the motion; the Court having reviewed the submissions of the parties in connection with the motion; pursuant to Fed. R. Civ. P. 78; for the reasons set forth in the Opinion being filed on even date; and for good cause shown;

**IT IS** on this 27<sup>th</sup> day of June, 2017,

**ORDERED** that Defendants’ Motion to Dismiss is **GRANTED**, and Relator’s Fourth Amended Complaint is **DISMISSED**.

/s/ Freda L. Wolfson  
\_\_\_\_\_  
Hon. Freda L. Wolfson, U.S.D.J.